Trial Name Description
HOPE Trial Prostate Dr. L. Mendez
Is hypofractionated whole-pelvis radiotherapy (WPRT) as well tolerated as conventionally-fractionated WPRT in prostate cancer patients?
PCS 6 Dr. D'Souza
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI).
PCS IX Dr. Michael Lock
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial (PCS IX)
ARASTEP GU Dr. E. Winquist
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
PROTRACT GU Dr. E. Winquist
Not open yet - PROTRACT (Prostate Cancer Treatment Optimization via Analysis of Circulating Tumour DNA) Study: A Randomized Phase II Trial Comparing Biomarker Directed Therapy versus Clinician's Choice of Enzalutamide or Docetaxel in Patients with Advance
IND.223 Dr. Eric Winquist
A Phase II Study of Palbociclib, A CDK 4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer.
Litespark GU Dr. E. Winquist
A multicenter, double-blind, randomized phase 3 study to compare the efficacy and safety of Belzutifan (MK-6482) plus Pembrolizumab (MK-3475) versus placebo plus Pembrolizumab, in the adjuvant treatment of clear cell renal cell carcinoma p
PERFORM Renal Dr. R. Fernandes
Preventing Immune-Related Adverse Events in Renal Cell Carcinoma Patients Treated with Combination Immunotherapy using Fecal Microbiota Transplantation
Renal mTor Dr. M. Haeryfar
Regulation of T cell responses by inhibitors of mammalian target of rapamycin (mTOR)
REaCT-HOLD BMA Dr. R Fernanes
A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer. (REaCT-Hold BMA)
ARGOS/CLIMBER GU Dr. Glenn Bauman
PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER)
IND.234 Dr. Eric Winquist
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study.
CONTACT-02 GU Dr. R. Fernandes
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
TROPICS-04 Bladder Dr. R. Fernandes
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
BL.13 Dr. Eric Winquist
A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients With Muscle-Invasive Bladder Cancer.
AQuOS-II (GU) Dr. Lucas Mendez
Assessment of Quality of Life and Outcomes in Patients Treated with Stereotactic Body Radiotherapy (SBRT) for Primary Renal Cell Carcinoma (RCC): AQuOS-II
EMT Prostate Dr. Alison Allan
Dynamic influence of the epithelial-to-mesenchymal transition (EMT) on circulating tumor cell (CTC) generation, phenotype, and disease progression in prostate cancer.
PEACE III GU Dr. E. Winquist
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone
ALPACA Penile Dr. E. Winquist
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy
CYTOSHRINK GU Dr. Eric Winquist
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer.
EV-302 GU Dr. Ricardo Fernandes
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.
MOUNTAINEER-02 Dr. D. Breadner
A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2
PR.24 Dr. Lucas Mendez
Not Open Yet - ANDROGEN SUPPRESSION COMBINED WITH ELECTIVE NODAL IRRADIATION AND DOSE ESCALATED PROSTATE TREATMENT: A NON-INFERIORITY, PHASE III RANDOMIZED CONTROLLED TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VERSUS BRACHYTHERAPY BOOST IN PATIENTS WITH
RADIANT Bladder Dr. R. Fernandes
Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI4736) prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Carcinoma
PR.19 Dr. Joelle Helou
A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer.
EvoPAR-Prostate01 Dr. R. Fernandes
A Randomized, 2-Cohort, Double-blind, Placebo-Controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer
CYTOSHRINK Renal Dr. E. Winquist
Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer